Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?

Annals of Thoracic and Cardiovascular Surgery

Volumn 17, Issue 5, 2011, Pages 454-460

  Kita, Hidefumi ^a   Shiraishi, Yuji ^a   Watanabe, Kenichi ^b   Suda, Kazuharu ^c   Ohtsuka, Kouki ^d   Koshiishi, Yoshihiko ^e   Goya, Tomoyuki ^d  

^a Japan Anti Tuberculosis Association   (Japan)

^b Sagamihara Kyoudou Hospital   (Japan)

^c Nagaoka Central General Hospital   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e International University of Health and Welfare   (Japan)

Author keywords

Early recurrence; Interluekin 6 (il 6); Lung cancer

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; JAPAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TUMOR; MALE; METASTASIS; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; UPREGULATION;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 80054928023     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: 10.5761/atcs.oa.10.01627     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell iung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer 2005; 50: 227-34.
3. Mountain CF. Revisions the international system for staging lung cancer. Chest 1997; 111: 1710-7.
4. Miki C, Tanaka K, Inoue Y, et al. Perioperative hosttumor inflammatory interactions: A potential trigger for disease recurrence following a curative resection for colorectal cancer. Surg Today 2008; 38: 579-84.
5. Higashiyama A, Watanabe H, Okumura K, et al. Involvement of tumor necrosis factor alpha and very late activation antigen 4/vascular cell adhesion molecule-1 interaction in surgical-stress-enhanced experimental metastasis. Cancer Immunol Immunother 1996; 42: 231-6.
6. ten Kate M, Hofland LJ, van Grevenstein WM, et al. Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelim. Int J Cancer 2004; 112: 943-50.
7. International Union Against Cancer. Lung Tumors. In: Sobin LH, Wittekind CH, editors. TNMclassification of Malignant Tumors. 5th edition. New York: Wiley-Liss 1997; pp 91-7.
8. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology. Brain Behav Immun 2003; 17: S27-36.
9. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10: 972-92.
10. Lee HJ, Jo J, Son DS, et al. Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection. J Korean Med Sci 2009; 24: 824-30.
11. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects tumor proliferative activity in colorectal cancer patients. Cancer 1999; 85: 2526-31.
12. Syk I, Mangell P, Bjartell A, et al. Systemic interleukin- 6 response to colorectal surgery originates from the bowel. Dig Surg 2002; 19: 210-5.
13. Watson JM, Sensintaffar JL, Berek JS, et al. Constitutive production of IL-6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990; 50: 6959-65.
14. Takizawa H, Ohtoshi T, Ohta K, et al. Growth inhibition of human lung cancer cell lines by interleukin-6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 1993; 53: 4175-81.
15. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-5.
16. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997; 72: 149-54.
17. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-91.
18. Pieter S, Martijn S, Kees DL. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. Br J Haematol 1991; 79: 589-94.
19. Alberti L, Thomachot MC, Bachelot T, et al. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004; 111: 653-61.
20. Oka M, Iizuka N, Yamamoto K, et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16: 1001-6.
21. Miki C, Tonouchi H, Wakuda R, et al. Intra-tumoral interleukin-6 down-regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma. Cancer 2002; 94: 1584-92.
22. De Vita F, Orditura M, Auriemma A, et al. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998; 5: 649-52.
23. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutitional status as progbostic factors in lung cancer. Cytokine 1999; 11: 80-6.
24. Cruickshank AM, Fraser WD, Burns HJ, et al. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161-5.
25. Sakamoto K, Arakawa H, Mita S, et al. Elevation of circulating interleukin 6 after surgery. Factors influencing the serum level. Cytokine 1994; 6: 181-6.
26. Yim AP, Wan S, Lee TW, et al. VATS lobectomy reduce cytokine responses compared with conventional surgery. Ann Thorac Surg 2000; 70: 243-7.
27. Nagahiro I, Andou A, Aoe M, et al. Pulmonary function, postoperative pain, and serum cytokine level after lobectomy. A comparison of VATS and conventionl procedure. Ann Thorac Surg 2001; 72: 362-5.
28. Craig SR, Leaver HA, Yap PL, et al. Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiovasc Surg 2001; 20: 455-63.